CYTK - Cytokinetics Inc. Debt to Book Capitalization Ratio

Cytokinetics (CYTK) revenues are based on bringing advanced treatments for muscle pathologies to market, including the drug aficamten, which is supported by the asset's market value of 0.00 as illustrated on this chart. However, a high burn rate and strict regulatory oversight pose serious threats to the share price. The company is currently finalizing the development stage as it prepares for the large-scale commercial launch of its innovative products.

CYTK (Cytokinetics Corp) Debt to Book Value history from 07/04/2022 to 10/27/2026

Cytokinetics Inc. (CYTK) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Cytokinetics|CYTK - Analyst Consensus Forecast

- market capitalization data:

Market Value Cytokinetics Corp|CYTK - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Cytokinetics|CYTK - Company Net Assets|Market Capitalization to Book Value Ratio cytokinetics.com|CYTK - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Cytokinetics|CYTK - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cytokinetics Inc|CYTK - Company Aggregate Debt|Debts to Book Capitalization Cytokinetics Corp

Fundamental company analysis:Cytokinetics - CYTK

During fundamental asset screening, this indicator allows for an assessment of financial leverage and the stability of the capital structure. By analyzing the dynamic debt-to-book capitalization ratio, an investor can determine the proportion of borrowed funds relative to the value of equity, which is critical for Cytokinetics (CYTK); in an environment of fierce competition with pharma behemoths, excessive leverage could amplify risks should any delays occur in clinical trials.

Competitors of Cytokinetics (CYTK)